By Scott Hensley
It's taken as self-evident that catching a disease early is always better than finding out about it late. But that dogma can be dead-wrong, according to an analysis of data on prostate cancer and the blood test used to screen for the disease.
A PSA test can detect a prostate cancer like this one, but it can't tell which form it is. As a result, physicians order treatment that's unneccessary, but with considerable side effects. (Visuals Unlimited/Corbis)
Widespread use of the PSA test in the U.S. began in 1986, and since then, it's led to the diagnosis of prostate cancer in 1.3 million men. The biggest jump in diagnosis occurred in men younger than 50, and more than 1 million were treated for the illness.
Problem is the "vast majority of these additional men did not benefit from early detection," according to the analysis published in the current Journal of the National Cancer Institute.
In other words, despite the 1.3 million diagnoses, only 56,000 deaths were averted.
Huh? The conundrum for screening is that so many prostate cancers detected by PSA never pose a health problem because they grow so slowly. A man dies of something else first. The most deadly forms of prostate cancer can progress so rapidly that even a positive PSA test doesn't necessarily help.
Continue reading "Study: Prostate Cancer Test Leads To Overtreatment" >
categories: Cancer, Public Health





